fluconazole has been researched along with Otomycosis in 5 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Otomycosis: Fungus infection of the external ear, usually by ASPERGILLUS species
| Excerpt | Relevance | Reference |
|---|---|---|
| " The evidence is very uncertain about the effect of clotrimazole on clinical resolution of otomycosis, on significant adverse events or other (non-serious) adverse events when compared with other topical azoles (eberconazole, fluconazole, miconazole)." | 5.12 | Topical azole treatments for otomycosis. ( Lee, A; Saeed, SR; Tysome, JR, 2021) |
| "Otomycosis is frequently seen in Shanghai and is a challenging problem due to recurrence and resistance to therapy." | 1.38 | Otomycosis in Shanghai: aetiology, clinical features and therapy. ( Cao, W; Chi, F; Jia, X; Liang, Q, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amona, FM | 1 |
| Wend-Lasida Ouedraogo, R | 1 |
| Sangare, I | 1 |
| Elola, A | 1 |
| Kiakojuri, K | 1 |
| Mahdavi Omran, S | 1 |
| Roodgari, S | 1 |
| Taghizadeh Armaki, M | 1 |
| Hedayati, MT | 1 |
| Shokohi, T | 1 |
| Haghani, I | 1 |
| Javidnia, J | 1 |
| Kermani, F | 1 |
| Badali, H | 1 |
| Abastabar, M | 1 |
| Lee, A | 1 |
| Tysome, JR | 1 |
| Saeed, SR | 1 |
| Kamali Sarwestani, Z | 1 |
| Hashemi, SJ | 1 |
| Rezaie, S | 1 |
| Gerami Shoar, M | 1 |
| Mahmoudi, S | 1 |
| Elahi, M | 1 |
| Bahardoost, M | 1 |
| Tajdini, A | 1 |
| Abutalebian, S | 1 |
| Daie Ghazvini, R | 1 |
| Jia, X | 1 |
| Liang, Q | 1 |
| Chi, F | 1 |
| Cao, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis[NCT01993823] | Phase 3 | 190 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The secondary efficacy variables include:~Proportion of subjects with signs and symptoms score of 0 at Day 15~Proportion of subjects with signs and symptoms score of 0 at Day 24~Proportion of subjects with a negative culture for fungus or presumed eradication (mycological cure) on Day 24." (NCT01993823)
Timeframe: 2 weeks and 4 weeks
| Intervention | percentage of patient (Number) | ||
|---|---|---|---|
| Signs and symptoms score 0 at Day 15 | Signs and symptoms score 0 at Day 24 | Mycological cure at Day 24 | |
| Clotrimazole | 77.65 | 86.08 | 97.65 |
| G238 | 59.55 | 85.83 | 96.63 |
"Efficacy will be assessed primarily by evaluation of the fungal culture, and the sum of signs and symptom scores (pruritus, otalgia, otorrhea and aural fullness obstruction to be scored as 0=absent; 1= mild; 2=moderate; 3=severe). The primary efficacy variable is the proportion of subjects with a negative culture for fungus, AND a signs and symptom score of 0 on Day 24.~Response to the study treatment was classed according to the following definitions:~Complete response: Negative fungal culture or presumed eradication on day 24, and sum score for signs and symptoms = 0 on day 24.~Partial response: Negative culture or presumed eradication on day 24, and sum score for signs and symptoms = 1 or 2 on day 24.~No response: Positive culture on day 24 or negative culture or presumed eradication and sum score for signs and symptoms > 2 on day 24." (NCT01993823)
Timeframe: Day 24
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | No-response | Missing data | |
| Clotrimazole | 66 | 11 | 2 | 6 |
| G238 | 72 | 11 | 5 | 1 |
1 review available for fluconazole and Otomycosis
| Article | Year |
|---|---|
Topical azole treatments for otomycosis.
Topics: Administration, Topical; Adult; Antifungal Agents; Bias; Child; Clotrimazole; Cycloheptanes; Flucona | 2021 |
4 other studies available for fluconazole and Otomycosis
| Article | Year |
|---|---|
The Role of Candida Albicans in Routine Clinically Suspected Otomycosis.
Topics: Antifungal Agents; Candida; Candida albicans; Drug Resistance, Fungal; Fluconazole; Humans; Microbia | 2021 |
Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.
Topics: Amphotericin B; Antifungal Agents; Candida; Drug Resistance, Fungal; Fluconazole; Humans; Microbial | 2021 |
Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Aspergillus niger; Clotrimazole; Female; | 2018 |
Otomycosis in Shanghai: aetiology, clinical features and therapy.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Child; Child | 2012 |